is...(vegasvic1)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RELAX IT IS BEING SHORTED..THE REAL TRUTH IS 35 MIL IN RESERVES EQUALS 89.8 MIL IN PROFITS GUARANTEED NEXT YEAR PLUS...
THEY HAVE TO COVER AT SOME POINT.
WHY???...
REMEMBER BUY LOW SELL HIGH..
WHEN EVERYONE LEAVES THAT IS THE TIME...
NOW IS THE TIME..
REMEMBER MY NAME I AM SELDOM WRONG..
shorts must cover soon...wait till close & up we go...buy more...now i am.. market cap is almost nothing compared to 2013 earnings..what a buy here..
just another way to dilute stock without saying it and keeping inexperienced traders in stock.i will wait for new co. and buy
commerce biz.
u r right but they r not giving equal shares of new co.
100k shares of mwiup equals 600 shares maybe.
but mwip will still have 444 mil shares which is worse than diluting a stock. the new co. will ezly do 150 mil next year with no return to mwip shareholders.
r they not forming 2 separate entities & splitting mwip.
what is the logic. if u separate the 10 mil sales from mwip as of yesterday the stock would b .005 again.
please give me 1 reason to do what they r doing.
NOT A SCARE TACTIC BUT REALITY. SHOW ME WHERE IT STATES THEIR SETTING UP A NEW DIVISION OF MWIP.
I HAVE NO INTEREST EITHER WAY.
I ORIGINALLY LOVED THE POTENTIAL BUT LIKE I SAY ASK AN ATTORNEY OF BUSINESS LAW TO DECIPER IT.
YES....BUT
THEY ARE TAKING THEIR BIGGEST ASSET & SEPARATING IT FRM MWIP.
NO REVENUES WILL FLOW THRU MWIP.
THEY WILL LEAVE SHAREHOLDERS OF MWIP WITH 444 MIL SHARES WITH 0 REVENUE STREAM
THEY R GIVING CRUMBS TO CURRENT SHAREHOLDERS. THE BUY WILL BE IN NEW COMPANY.
SEEN THIS MANY TIMES B4.
DATE HAS BEEN SET READ 10Q......
IF U CAN.T UNDERSTAND WHAT IT MEANS BETTER GET ENGLISH TEACHER TO EXPLAIN IT. THEY MADE IT VAGUE BUT EXPLICIT.
HAD LAWYERS EXPLAIN IT.
On October 11, 2012, the Board of Directors of the Company approved the distribution to shareholders on a pro-rata basis of the six million (6,000,000) shares of common of 800 Commerce, owned by the Company (the “Distribution”). 800 Commerce filed an S-1 Registration Statement on October 17, 2012 with the Securities and Exchange Commission (“SEC”). Upon approval from the SEC, the Company and other regulatory approvals required, the Company will announce a shareholder record date, whereby shareholders of the Company as of that date will be entitled to their pro-rata share of the Distribution.
On October 25, 2012, the holder of the Company’s convertible debt converted $15,000 of the April 2012 Note into 10,714,286 shares of common stock at approximately $0.0014 per share. As a result, the outstanding Series B preferred stock is convertible into an additional 5,892,857 shares of common stock, for an aggregate of 250,185,190 shares of common stock.
Management performed an evaluation of the Company’s activity through the date these financials were issued to determine if they must be reported. The Management of the Company determined that there were no other reportable subsequent events to be disclosed.
FROM QUARTERLY REPORT....IF U BOUGHT AFTER OCT. 17TH READ...
On October 11, 2012, the Board of Directors of the Company approved the distribution to shareholders on a pro-rata basis of the six million (6,000,000) shares of common of 800 Commerce, owned by the Company (the “Distribution”). 800 Commerce filed an S-1 Registration Statement on October 17, 2012 with the Securities and Exchange Commission (“SEC”). Upon approval from the SEC, the Company and other regulatory approvals required, the Company will announce a shareholder record date, whereby shareholders of the Company as of that date will be entitled to their pro-rata share of the Distribution.
On October 25, 2012, the holder of the Company’s convertible debt converted $15,000 of the April 2012 Note into 10,714,286 shares of common stock at approximately $0.0014 per share. As a result, the outstanding Series B preferred stock is convertible into an additional 5,892,857 shares of common stock, for an aggregate of 250,185,190 shares of common stock.
Management performed an evaluation of the Company’s activity through the date these financials were issued to determine if they must be reported. The Management of the Company determined that there were no other reportable subsequent events to be disclosed.
KEY WORDS...AS OF THAT DATE..
ONCE THEY TAKE OUT 800 COMMERCE THERE IS NOTHING LEFT OF VALUE TO MWIP EXCEPT 444 MIL SHARES DILUTED TO ??????
SMELLS FISHY IM OUT.
GERALDS WAITING 2 C IF MAYANS WERE RIGHT BEFORE HE PUTS OUT THE GREAT NEWS....
WINTER....NEWS...NEWS....NEWS....
NEWS OUT TOMORROW OR MON. BOAT IS LEAVING THE DOCK.....ALL ABOARD
NO TURNING BACK AFTER TODAY....
PATIENCE...WITH THESE NEW NUMBERS BIG THINGS R COMING...REMEMBER
IT IS A PENNY STOCK...NOT MANY SHOW RENENUES..THIS IS HUGE.
COULDN'T BE HAPPIER....
EVEN THE LONGS...SHORTS.....FLIPPERS HANGING AROUND.
I SEE A NEWS RELWEASE MID DAY TODAY...
WATCH THE SCRAMBLE...THEN WE SELL ON THEM...
crow we are in vegas spending your $$$$.
WHERE IS THE CONNECTION TO RAFFERTY. WHERE CAN I FIND IT.
GE CAPITAL FUNDS CARE CREDIT....READ
MY GIRLFRIEND NEEDED ELECTIVE SURGERY IN VEGAS HER P;ASTIC SURGEON REFERRED HER TO CARE CREDIT FOR THE 10K LOAN
FRIEND IN CAL. NEEDED LASIK FOR $8K GOT LOAN THRU CARE CRDIT.
MWIP IS GOING TO BE HUGE. THE MARKET FOR ELECTIVE SURGERIES IS ENDLESS. IF GE BACKS CARE CREDIT.. GUESS WHAT..
AMERICAN EXPRESS ONLY DEALS WITH THE BEST OF THE BEST..
A TRUE WINNER IN MONTHS TO COME.
tHEIR DEC. SALES WILL TRIPLE NOV.
& SO ON & SO ON...
NOT THIS WEEK OR NEXT...DUHHHH.
HOW HARD IS IT TO HIRE AN AUDIT FIRM...UNLESS......NOBODY WANTS THE JOB. IT HAS BEEN 2 MONTHS SINCE THEY REPORTED THEY WERE GOING TO HIRE ONE.
NEWS...THERE IS NONE...HARD TO REPORT NOTHING....
THE WAY TO PLAY PENNY STOCKS WITH HUGE UPSIDE IS TO OWN THEM EARLY.
WHEN THE NEWS IF GOOD HITS BUY MORE @ HIGHER PRICE & TRADE THEM FOR A PROFIT,
KNOWING AMBS IS COMING OUT WITH NEWS THIS WEEK & WAITING IS LUDICROUS. ANY STOCK THAT HAS NEWS PENDING GOES UP 7-10 DAYS BEFORE REPORTS.
CANNOT GO DOWN..IMPOSSIBLE.
PLEASE READ DIFFERENT PERSPECTIVE THAT NO ONE DISCUSES HERE.....
If u read my post about Banyan Biomarkers they are getting govt. grants for developing a test for TBI.
How much is the govt. willing to pay for a medical solution for treatment of TBI.
ANSWER... A LOT MORE.
GRANTS COMING. I BELIEVE THE REAL STORY WITH AMBS IS TBI
WITH ALL THE TRAUMA CASES EVERY DAY NFL...ALL SPORTS...AUTO ACCIDENTS..AND SO ON.
TBI & BANYAN ARE THE LEADERS IN THE FIELD FOR TBI & THEY JUST
HAPPEN TO BE WORKING TOGETHER.
THIS IS GONNA HAPPEN A LOT SOONER THAN PARKINSONS.
AMBS IS BUILDING A COMPANY EQUAL TO AMGEN OR BIGGER IN BIO TECH
BUT IF YOU DONT HAVE THE CEO'S VISION U LOSE.
If that's the case he is wasting his time.
The downside is negliable but the upside is life changing.
I would not want to be the person waiting for this to go down.
If u read my post about Banyan Biomarkers they are getting govt. grants for developing a test for TBI.
How much is the govt. willing to pay for a medical solution for treatment of TBI.
ANSWER... A LOT MORE.
GRANTS COMING. I BELIEVE THE REAL STORY WITH AMBS IS TBI
WITH ALL THE TRAUMA CASES EVERY DAY NFL...ALL SPORTS...AUTO ACCIDENTS..AND SO ON.
TBI & BANYAN ARE THE LEADERS IN THE FIELD FOR TBI & THEY JUST
HAPPEN TO BE WORKING TOGETHER.
THIS IS GONNA HAPPEN A LOT SOONER THAN PARKINSONS.
AMBS IS BUILDING A COMPANY EQUAL TO AMGEN OR BIGGER IN BIO TECH
BUT IF YOU DONT HAVE THE CEO'S VISION U LOSE.
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
Read more: Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury - FierceBiotech http://www.fiercebiotech.com/press-releases/banyan-biomarkers-inc-awarded-26-3-million-department-defense-contract-diagnostic-tes#ixzz2FEkAFuiS
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
SUNNYVALE, Calif. and ALACHUA, Fla., June 7, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
go to google banyan bio & u can read 4 yourself.
THE BIGGER PICTURE IS TBI traumatic brain injury,
ADD UP INJURIES TO BRAIN....IT IS UNLIMITED.
NOW DO IT WORLDWIDE.
AMBS IS THE ONLY BIO I KNOW OF WITH A PATENT FOR A POSSIBLE SOLUTION TO THE PROBLEM.
IT WILL TAKE PARKINSON A TIME TO DEVELOP
TBI VERY QUICKLY & PATENTS WILL BE GOBBLED UP VERY SOON.
AMBS WILL BE SOLD & WE ALL HOLD THE WINNING LOTTERY NUMBERS.
I HAVE DONE THIS WITH OVER 20 BIO TECHS, jazz mdvn ex.
this is the biggest i have ever seen.
THIS IS BIGGER THAN ANYONE OTHER THAN GERALD CAN IMAGINE.
HE IS DEIGNING AND DEVELOPING ANOTHER AMGEN.
THAT IS WHY HE HAS SO MUCH SUPPORT FROM PROMINENT LEADERS IN THE BIO TECH INDUSTRY.
WITH THE NFL & OTHER SPORTS TEAMS & THE GOVT. TBI IS HUGE.
I USUALLY THINK AHEAD OF THE PACK.
THERE IS A FORTUNE TO BE MADE HERE.
WHEN OBAMA LOWERED THE MEDICAL STANDARDS FOR DRUG APPROVAL WHEN HE GOT ELECTED HE MADE A HUGE DIFFERENCE ID DRUGS APPROVED.
THIS WILL GIVE AMBS ORPHAN DRUG APPROVAL GUARANTEEDD.
OCT. 22, 2012 MUST READ BANYAN BIO CEO INTERVIEW.
HE USES ALL THE SAME LANGUAGE THAT AMBS USES
DEFINITE CORRELATION & BIG THINGS COMING WITH GOVT GRANTS,
CEOCFO: How does the brain injury test work and what is the technology?
Dr. Streeter: It is much like testing that is done for people that come into the emergency room with chest pain. There is a blood test that identifies proteins that come from the heart and we are doing something very similar to that except that we are doing a blood test which identifies proteins that come from the brain. Testing of proteins like this is routine for other organs and particularly for the heart and now, we have developed the test very similar to that for the brain.
CEOCFO: Is this a new concept for the brain?
Dr. Streeter: The idea of it is not particularly revolutionary, but identifying proteins and validating assays clinically is something not done before and we are doing for the first time.
CEOCFO: How are you able to identify them and why has this been an unexplored concept?
Dr. Streeter: Banyan is spun from the McKnight Brain Institute where our scientific founder Dr. Ron Hayes was responsible for the early discoveries. He ran the center for traumatic brain injury studies there before he founded Banyan. At the University of Florida they made the discovery that there are a couple of brain specific proteins. One protein comes from the neuron which is the cell type that fires electrical impulses which allow us to think and move and all that. The other comes from the astrocyte, which is a cell that is responsible for supporting the neurons inside the brain. We are detecting two proteins that come from the two major cell types in the brain, so that is very nice coverage of the organ.
ANYONE HAVE OTHER INPUT.
MUST READ... Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
If the Governemnt is giving grants to Banyan for trying to find a test for TBI what would they be giving for treating it?
NO ONE EVER MENTIONS BANYAN BIO.
AMBS HAS BEEN WORKING WITH THEM ON TBI SINCE 2011.
I see a govt.grant in the future.
TBI is huge. Just as big if not bigger than Parkinsons.
TBI is where the real $$$$ is.
AMBS has MANF & patents.
That is why the control of MANF was so important.
Anyone have other input.
Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
Newswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF's potential as a disease-modifying agent for the treatment of TBI.
"Based on the results produced through this collaboration, we are excited about the potential of the MANF Program in generating new products to treat concussions and other forms of TBI," said Gerald Commissiong , President & CEO of Amarantus. "While this data is early on in development, we will be looking for innovative approaches to accelerate our TBI development program, while using Banyan's proprietary panel of markers as a key metric in our companion drug – diagnostic strategy."
In in-vitro cell culture experiments, MANF was reproducibly shown to confer neuroprotective properties in various cell death-related pathways. The data raise the possibility that modulating MANF in patients immediately after suffering a TBI and in patients who have suffered multiple concussions over an extended period, could be a successful therapeutic approach to promote recovery after TBI.
"The data shows that MANF has a significant ability to reduce cell death from a variety of insults that simulate Traumatic Brain Injury as we have modeled in multiple assays in our internal laboratories at Banyan," said Dr. Andreas Jeromin , PhD, Senior Director Research at Banyan, "These data give us confidence to move to the next phase of testing to further validate this approach, as well as look at innovative product development strategies to accelerate bringing a MANF-based treatment to patients for TBI."
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
If the Governemnt is giving grants to Banyan for trying to find a test for TBI what would they be giving for treating it?
I see a govt.grant in the future.
TBI is huge. Just as big if not bigger than Parkinsons.
TBI is where the real $$$$ is.
AMBS has MANF & patents.
That is why the control of MANF was so important.
Anyone have other input.
THE CONNECTION BETWEEN BANYAN & AMBS IS VERY STRONG BUT NEVER MENTIONED???
MAYBE GOVT. MIGHT GIVE GRANT SINCE AMBS IS WORKING ON TBI ALSO.
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
Share
Tools
Print
Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury
ALACHUA, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.
This award will help fund critical research for a point of care test to diagnose TBI and has significant potential for both military and civilian applications. Jackson Streeter, M.D. and CEO of Banyan Biomarkers, Inc. stated, "We are pleased to be working with the Department of Defense to develop a blood test for TBI. Properly diagnosing TBI will help medical professionals triage and treat our soldiers more effectively."
Each year in the United States, approximately 1.4 million people are treated in emergency rooms because of TBI. Automobile accidents, falls, sports related injuries, and assaults are common causes of TBI. It is estimated that as many as 20% of combat veterans have suffered some degree of traumatic brain injury due to bomb blasts while in Iraq or Afghanistan.
Read more: Banyan Biomarkers, Inc. Awarded $26.3 Million Department of Defense Contract for Diagnostic Test for Traumatic Brain Injury - FierceBiotech http://www.fiercebiotech.com/press-releases/banyan-biomarkers-inc-awarded-26-3-million-department-defense-contract-diagnostic-tes#ixzz2F6Itwxdk
Subscribe: http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech
Amarantus BioSciences and Banyan Biomarkers Announce Positive ...
www.prnewswire.com/.../amarantus-biosciences-and-banyan-biomar...
Jun 7, 2012 – Amarantus BioSciences and Banyan Biomarkers Announce Positive Data from Traumatic Brain Injury Collaboration
point of care blood tests banyan bio.
2 news stories on google.
how come ambs does not mention banyan biomarkers when they are working with them closely?
does anyone know more???
GO AMBS
Point-of-Care Blood Test, Banyan Biomarkers, Inc.
google 2 articles and there is a great connection for ambs.
Amarantus BioSciences and Banyan Biomarkers Announce Positive ...
DO NOT WAIT 2 LONG WE ARE GOOD AT LEAST TILL JAN. 8-10TH 2013.